Progressive Supranuclear Palsy Market Size and Overview
The global progressive supranuclear palsy (PSP) market, valued at USD 231 million in 2025, is projected to reach USD 313 million in 2026 and USD 492 million by 2030, with a 11.9% CAGR during the forecast period, 2026 to 2030.
To learn more about this report, request a free sample copy
The “Progressive Supranuclear Palsy: Pipeline Review, Developer Landscape and Competitive Insights, Till 2030” report features an extensive study on the marketed, clinical and preclinical molecules available / being developed for the treatment of Progressive Supranuclear Palsy.
This report provides an in-depth analysis of the product pipeline and developer companies, highlighting the current treatment practices, emerging drugs, and market share of the individual therapies. In addition to other elements, the study includes detailed assessment of the current market landscape, providing information about the product’s mechanism of action, dosage and administration, and pharmacological studies, regulatory milestones, and other development activities.
One of the key objectives of the report was to estimate the existing market size and the future opportunity of therapies for Progressive Supranuclear Palsy, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of the forecasted therapies and the likely selling price of such therapeutic products, we have provided informed estimates on the evolution of the market for the period till 2030.
Recent Developments in Progressive Supranuclear Palsy (PSP) Therapies Market:
Several recent developments have taken place in the field of Progressive Supranuclear Palsy (PSP) Therapies. We have outlined some of these recent initiatives below. These developments, even if they took place post the release of our market report, substantiate the overall market trends that have been outlined in our analysis.
- In June 2025, Ferrer announced that FDA granted Fast Track designation to its investigational therapy FNP-223 for slowing disease progression in progressive supranuclear palsy, underpinned by an ongoing Phase 2 trial in PSP-Richardson syndrome patients.
Progressive Supranuclear Palsy Market Trends and Scope
- A detailed assessment of the therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and mechanism of action across the complete product development cycle, including all clinical and nonclinical stages.
- Detailed profiles of the players that are engaged in the development of drug products / therapies for Progressive Supranuclear Palsy, featuring overview of the company, its financial information (if available), a description of its product portfolio, recent collaborations and an informed future outlook.
- An insightful market assessment summary, highlighting the clinical and commercial attractiveness of pipeline molecules (phase II and phase III), taking into consideration size of enrolled patient population, route of administration, treatment type and dosing frequency, and target patient population, expected launch date and size of developer company.
- A detailed analysis identifying the key opinion leaders (KOLs), featuring a 2X2 analysis to assess the relative experience of certain KOLs who were shortlisted based on their contributions (in terms of involvement in various clinical studies) to this field.
- An analysis of the partnerships that have been established in the domain, over the last five years, covering research agreements, product / technology licensing agreements, mergers / acquisitions, asset purchase agreements, R&D and commercialization agreements, IP licensing agreements, clinical trial agreements, product development agreements, and other relevant deals.
- An analysis of the investments made at various stages of development, such as seed financing, venture capital financing, debt financing, grants / awards, capital raised from IPOs and subsequent offerings, by companies that are engaged in this field.
- A detailed analysis of completed, ongoing and planned clinical studies, based on the various relevant parameters, such as trial registration year, trial phase, number of patients enrolled, study design, trial recruitment status, and trial focus, highlighting leading sponsors, type of organization, and regional distribution of trials. In addition, it features an insightful clinical end-points analysis.
Key Questions Answered
- What are the prevalent R&D trends related to Progressive Supranuclear Palsy?
- What are the key challenges faced by stakeholders engaged in this domain?
- What are the principal therapies developed by the companies in this domain?
- Who are the leading industry and non-industry players in this market?
- What are the contributions of big pharma players in this field?
- What are the key geographies where research on Progressive Supranuclear Palsy is being conducted?
- Who are the key investors in this domain?
- Who are the key opinion leaders / experts in this field?
- What kind of partnership models are commonly adopted by industry stakeholders?
- What are the factors that are likely to influence the evolution of this upcoming market?
- How is the current and future market opportunity likely to be distributed across key market segments?
You may also be interested in the following titles:
Concussion Market
Spinocerebellar Ataxias Market
Friedreich's Ataxia Market
